**GE**

# OPTISON™
(Perflutren Protein-Type A Microspheres Injectable Suspension, USP)

# Since 1997, over 3 million doses shipped worldwide[1]

**December 1997**

Approved by the FDA for ultrasound enhancing imaging in the US

**January 1998**

Launched as the first second-generation ultrasound enhancing agent for the US market

**May 1998**

Launched in the European market

**December 2002**

Transfer of Optison from Mallinckrodt Pharmaceuticals to Amersham Health

**April 2004**

GE Healthcare acquires Amersham Health

**November 2005**

GE Healthcare voluntarily recalled Optison due to manufacturing issues at Mallinckrodt

**November 2007**

Optison relaunched for US echocardiography market

**May 2008**

FDA revises Boxed Warning for ultrasound enhancing agents

**August 2012**

Positive updates to Optison label approved by the FDA

**December 2013**

1.5 million doses shipped worldwide in 15 years

**January 2014**

GE Healthcare moves manufacturing to company's Oslo site

**April 2016**

New 18-vial carton

**September 2016**

FDA removes cardiac shunt contraindication

**March 2021**

FDA approves storage at room temperature up to 24 hours

**July 2021**

Optison no longer requires temperature controlled shipping, though should be refrigerated upon receipt

**September 2021**

FDA removes blood and blood products hypersensitivity contraindication, further confirming Optison is not a blood product

---

**IMPORTANT SAFETY INFORMATION ABOUT OPTISON**

**WARNING: SERIOUS CARDIOPULMONARY REACTIONS**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration

• Assess all patients for the presence of any condition that precludes OPTISON administration

• Always have resuscitation equipment and trained personnel readily available

• **CONTRAINDICATION:** Do not administer OPTISON to patients with known or suspected hypersensitivity to perflutren or albumin.

**Please see Full Prescribing Information here for additional Important Safety Information About Optison.**